Single payer kills medical innovation---cost incentives, rationing, and picking winners
The Economist 7---The economist is an award winning magazine. 4/16/07, “In the name of innovation” https://www.economist.com/blogs/freeexchange/2007/04/in_the_name_of_innovation
Since we have made that argument on this very blog, I feel compelled to defend it from those who misunderstand it.
First of all, the argument is not that government never innovates, nor even that it never provides services better than the private sector. It is much more subtle than that. The problem is that when the government picks a winner, there is a very good chance that they will pick the wrong one. It is fun to scan all the various government agencies involved in providing health care and choose a single example of one with a good medical records system, and then proclaim that as a benefit of government provision. But one could perform the same feat on lots of private systems, provided one gets to choose the outliers. Yes, European government planning produced GSM cell phones . . . but it also produced Minitel.
Before you jump to a system where a single provider picks everything, you want to ensure it's a single provider that can do a better than average job. Libertarians are not particularly sanguine that the government is that provider . . . and indeed, many would say that a single provider never does the best job, except in a few narrow cases involving public goods, a category that health care simply doesn't fall into. (There are very few uncaptured positive externalities from heart surgery).
As for the me-too drugs . . . well, I find this argument bizarre enough that it inspired its own post, below.
Mr Klein's commenter is even more confusing. He needs to discuss healthcare with someone other than high school debaters. Then he would have heard the standard argument as to why government control of health care spending stifles innovation, which has little to do with government summarily outlawing new heart drugs.
The argument is this: government, being averse to raising taxes, needs to restrain cost growth. There are a number of ways they do this*.
Lower overhead (yes, free marketers, government health care systems do have lower overhead, though not as much lower as claimed by single-payer advocates)
Using monopsony bargaining power to drive down payments to doctors, hospitals, medical equipment providers, and drug companies. Single payer advocates describe this as "using negotiating power"; opponents call it "price controls". Take your pick, for they both describe the same thing: bullying workers and companies to sell for less than the competitive market price.
Ration treatment
The first probably doesn't have much effect on innovation, but the second two will, if basic economic laws hold, both drive down the number of new products. Driving down the per-unit cost, and curtailing the use of products, dramatically lowers the potential profit from inventing a new drug. At any given time, there are some drug candidates whose profit potential is marginal: it'll do okay, but it's no Lipitor. If you make the market smaller, and/or reduce the potential profit per unit, then some of those drugs will become unprofitable to pursue.
Meanwhile, government rationing adds another risk to an already risky business. Businesses assessing a new drug no longer need to wonder whether it will be one of the one in a thousand, or one in ten thousand, that makes it through FDA trials; now they also need to wonder whether it will make the government formulary. To believe that this will not happen is to believe that neither drug companies, nor the people who invest in them, do not care about making money on their products. This is an odd belief, especially since it is held by so many who castigate drug companies for their outrageous greed.
It is especially hard to argue against this effect from Medicare, as Mr Klein does, since one of the notable features of Medicare is that, until a few years ago, it didn't cover prescription drugs.